MOLECULAR MECHANISM OF HEMATOLOGICAL MALIGNANCY
血液恶性肿瘤的分子机制
基本信息
- 批准号:3200564
- 负责人:
- 金额:$ 24.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-03-04 至 1996-02-28
- 项目状态:已结题
- 来源:
- 关键词:T lymphocyte acute lymphocytic leukemia athymic mouse cell line chondrocytes complementary DNA disease /disorder model gene expression gene frequency gene induction /repression gene mutation human tissue laboratory mouse laboratory rat neoplasm /cancer genetics neoplasm /cancer relapse /recurrence neoplasm /cancer transplantation nucleic acid sequence oncogenes phenotype polymerase chain reaction retinoblastoma tissue /cell culture tumor suppressor genes
项目摘要
The mechanism of induction of acute lymphoblastic leukemia (T-ALL) is
not known. Nor do we know why T-ALL patients relapse with such high
frequency. If the molecular mechanism of induction and of relapse of
T-ALL were understood, it might be possible to design rational
strategies to reverse or cure this disease. Different mechanisms for
the induction of T-ALL have been proposed. One reasonable suggestion
targets dysregulation of differentiation as an initiating event.
Disregulation of differentiation of pro- or pre- T cells would cause
unscheduled cellular self-renewal and the abrogation of cell
senescence. In this application we show that dysregulation of
differentiation may be associated with the loss or mutation of
specific tumor suppressor (TS) genes. A study of the status of two
known TS genes in T-ALL cell lines has revealed that 60% of T-ALL
lines possessed mutated p53 TS genes, and 20% had lost the
retinoblastoma susceptibility gene product Rb. Furthermore, fresh T-
ALL samples have also been found to possess mutations of the p53
gene. The high incidence of loss of these TS genes among T-ALL
cells, and the relationship between the roles of p53/Rb and cell
differentiation/proliferation strongly suggest that mutation/loss of
the p53/RB genes, respectively, plays a significant role in the
induction and/or the recurrence of T-ALL. Therefore we propose to
study the mechanism of induction of T-ALL (i) by studying the status
of p53 in primary diagnosis and relapse T-ALL patient samples; (ii)
By studying the status of p53 in primary diagnosis and relapse
samples of the same patients to determine the relationship of p53
mutation and T-ALL cell "progression"; (iii) By studying the effects
of p53 on the differentiation of leukemic T blasts; and (iv) by
designing strategies for reversing the leukemic state of T-ALL cells
through the introduction of wild type p53 and/or Rb gene constructs.
Since all malignancy-conferring suppressor genes in T-cell
leukemogenesis appears to be the most promising approach to date for
achieving the biological reversion of the leukemic state.
急性淋巴细胞白血病(T-ALL)的诱发机制是
不知道。我们也不知道为什么T-ALL患者的复发率这么高
频率如果诱发和复发的分子机制
所有这些都是理解的,所以有可能设计出Rational
逆转或治愈这种疾病的策略。不同的机制
T-ALL的诱导已被提出。一个合理的建议
将分化失调作为启动事件。
T细胞前或前T细胞分化的失调将导致
细胞的非程序性自我更新与细胞的消灭
衰老。在本应用程序中,我们展示了
分化可能与基因缺失或突变有关。
特异性肿瘤抑制因子(TS)基因。关于两个国家地位的研究
T-ALL细胞系中已知的TS基因显示60%的T-ALL
具有突变的p53 TS基因的品系中,有20%的品系丢失了
视网膜母细胞瘤易感基因产物Rb。此外,新鲜的T-
所有样本也都被发现存在p53突变。
吉恩。T-ALL中TS基因缺失的高发率
细胞以及P53/Rb的作用与细胞的关系
分化/增殖强烈提示基因突变/缺失
P53/Rb基因分别在卵巢癌中起着重要作用。
T-ALL的诱导和/或复发。因此,我们建议
通过研究T-ALL的状态来研究T-ALL的诱导机制
P53在初诊和复发T-ALL患者样本中的表达;(Ii)
通过研究P53在初诊和复发中的地位
同一患者标本中P53蛋白的相关性研究
突变与T-ALL细胞“进展”;(Iii)通过研究
P53对白血病T细胞分化的影响;及
设计逆转T-ALL细胞白血病状态的策略
通过导入野生型P53和/或Rb基因构建。
由于T细胞中所有与肿瘤相关的抑制基因
白血病的发生似乎是迄今为止最有希望的治疗方法。
实现白血病状态的生物逆转。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Martin nmi Haas其他文献
Martin nmi Haas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Martin nmi Haas', 18)}}的其他基金
STUDIES OF AN AFRICAN POPULATION ENDEMIC FOR HTLV
非洲人群 HTLV 流行病的研究
- 批准号:
3183737 - 财政年份:1986
- 资助金额:
$ 24.88万 - 项目类别:
STUDIES OF AN AFRICAN POPULATION ENDEMIC FOR HTLV
非洲人群 HTLV 流行病的研究
- 批准号:
3183736 - 财政年份:1986
- 资助金额:
$ 24.88万 - 项目类别:
VIRAL MALIGNANT LYMPHOMAGENESIS IN X-IRRADIATED MICE
X 射线照射小鼠中的病毒恶性淋巴瘤发生
- 批准号:
3171912 - 财政年份:1982
- 资助金额:
$ 24.88万 - 项目类别:
VIRAL MALIGNANT LYMPHOMAGENESIS IN X-IRRADIATED MICE
X 射线照射小鼠中的病毒恶性淋巴瘤发生
- 批准号:
3171917 - 财政年份:1982
- 资助金额:
$ 24.88万 - 项目类别:
VIRAL MALIGNANT LYMPHOMAGENESIS IN X-IRRADIATED MICE
X 射线照射小鼠中的病毒恶性淋巴瘤发生
- 批准号:
3171915 - 财政年份:1982
- 资助金额:
$ 24.88万 - 项目类别:
VIRAL MALIGNANT LYMPHOMAGENESIS IN X-IRRADIATED MICE
X 射线照射小鼠中的病毒恶性淋巴瘤发生
- 批准号:
3171916 - 财政年份:1982
- 资助金额:
$ 24.88万 - 项目类别:
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 24.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 24.88万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 24.88万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 24.88万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 24.88万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 24.88万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 24.88万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 24.88万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 24.88万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 24.88万 - 项目类别: